• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    114.47 +3.40 (+3.06%)
    Streaming Delayed Price Updated: 12:44 PM EDT, Jun 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Mirum Pharmaceuticals, Inc. - common stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.